Relationship between visual acuity and spectral domain optical coherence tomography retinal parameters in neovascular age-related macular Degeneration

Ophthalmologica

Volumn 231, Issue 1, 2013, Pages 37-44

  Ristau, Tina ^a   Keane, Pearse A ^b   Walsh, Alexander C ^d   Engin, Alicia ^a   Mokwa, Nils ^a   Kirchhof, Bernd ^a   Sadda, Srinivas R ^c   Liakopoulos, Sandra ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MOORFIELDS EYE HOSPITAL   (United Kingdom)

^c DOHENY EYE INSTITUTE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Age related macular degeneration; Fluorescein angiography; Optical coherence tomography; Visual acuity

Indexed keywords

ARTICLE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PHOTORECEPTOR; RETINA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY; AGE RELATED MACULAR DEGENERATION; AGED; CORRELATIONAL STUDY; DISEASE SEVERITY; FUNCTIONAL MORPHOLOGY; IMAGING SOFTWARE; MEOVASCULAR AGE RELATED MACULAR DEGENERATION; NEOVASCULARIZATION (PATHOLOGY); QUANTITATIVE ANALYSIS; RETINAL THICKNESS; RETINAL VOLUME; RETROSPECTIVE STUDY; SUBRETINAL FLUID; VISUAL SYSTEM PARAMETERS;

AGED; ATROPHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; IMAGING, THREE-DIMENSIONAL; MACULAR EDEMA; MALE; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; WET MACULAR DEGENERATION;

RANIBIZUMAB;

EID: 84898596321     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000354551     Document Type: Article

References (25)

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431. (Pubitemid 44511557)
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444. (Pubitemid 44511558)
3. Bressler NM, Bressler SB, Congdon NG, Ferris FL 3rd, Friedman DS, Klein R, Lindblad AS, Milton RC, Seddon JM: Potential public health impact of Age-Related Eye Disease Study results: AREDS report No. 11. Arch Ophthalmol 2003; 121: 1621-1624. (Pubitemid 37392370)
4. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-583.
5. Sadda SR, Joeres S, Wu Z, Updike P, Romano P, Collins AT, Walsh AC: Error correction and quantitative subanalysis of optical coherence tomography data using computer-assisted grading. Invest Ophthalmol Vis Sci 2007; 48: 839-848. (Pubitemid 351260721)
6. Joeres S, Tsong JW, Updike PG, Collins AT, Dustin L, Walsh AC, Romano PW, Sadda SR: Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2007; 48: 4300-4307. (Pubitemid 351261062)
7. Keane PA, Liakopoulos S, Ongchin SC, Heussen FM, Msutta S, Chang KT, Walsh AC, Sadda SR: Quantitative subanalysis of optical coherence tomography after treatment with ranibizumab for neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49: 3115-3120.
8. Kashani AH, Keane PA, Dustin L, Walsh AC, Sadda SR: Quantitative subanalysis of cystoids spaces and outer nuclear layer using optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci 2009; 50: 3366-3373.
9. Keane PA, Liakopoulos S, Chang KT, Wang M, Dustin L, Walsh AC, Sadda SR: Relationship between optical coherence tomography retinal parameters and visual acuity in neovascular age-related macular degeneration. Ophthalmology 2008; 115: 2206-2214.
10. Landa G, Su E, Garcia PM, Seiple WH, Rosen RB: Inner segment-outer segment junctional layer integrity and corresponding retinal sensitivity in dry and wet forms of age-related macular degeneration. Retina 2011; 31: 364-370.
11. Einwallner E, Ahlers C, Golbaz I, Schutze C, Dunavolgyi R, Stock G, Schmidt-Erfurth UM: Neovascular age-related macular degeneration under anti-angiogenic therapy: subretinal fluid is a relevant prognostic factor (in German). Ophthalmologe 2010; 107: 158-164.
12. Bolz M, Simader C, Ritter M, Ahlers C, Benesch T, Prunte C, Schmidt-Erfurth U: Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration. Br J Ophthalmol 2010; 94: 185-189.
13. Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U: Relationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol 2008; 92: 361-364. (Pubitemid 351363531)
14. Kiss CG, Geitzenauer W, Simader C, Gregori G, Schmidt-Erfurth U: Evaluation of ranibizumab- induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 2009; 50: 2376-2383.
15. Ting TD, Oh M, Cox TA, Meyer CH, Toth CA: Decreased visual acuity associated with cystoid macular edema in neovascular agerelated macular degeneration. Arch Ophthalmol 2002; 120: 731-737. (Pubitemid 34620351)
16. Golbaz I, Ahlers C, Stock G, Schutze C, Schriefl S, Schlanitz F, Simader C, Prunte C, Schmidt-Erfurth UM: Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy. Invest Ophthalmol Vis Sci 2011; 52: 1599-1605.
17. Yaylali SA, Akcakaya AA, Erbil HH, Candemir B, Mesci C, Acar H: The relationship between optical coherence tomography patterns, angiographic parameters and visual acuity in age-related macular degeneration. Int Ophthalmol 2012; 32: 25-30.
18. Akagi-Kurashige Y, Tsujikawa A, Oishi A, Ooto S, Yamashiro K, Tamura H, Nakata I, Ueda-Arakawa N, Yoshimura N: Relationship between retinal morphological findings and visual function in age-related macular egeneration.Graefes Arch Clin Exp Ophthalmol 2012; 250: 1129-1136.
19. Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group: Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials. Ophthalmology 2013; 120: 1860-1870.
20. Sadda SR, Wu Z, Walsh AC, Richine L, Dougall J, Cortez R, LaBree LD: Errors in retinal thickness measurements obtained by optical coherence tomography. Ophthalmology 2006; 113: 285-293. (Pubitemid 43170778)
21. Ray R, Stinnett SS, Jaffe GJ: Evaluation of image artifact produced by optical coherence tomography of retinal pathology. Am J Ophthalmol 2005; 139: 18-29. (Pubitemid 40094836)
22. Patel PJ, Chen FK, Ikeji F, Xing W, Bunce C, Da Cruz L, Tufail A: Repeatability of stratus optical coherence tomography measures in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008; 49:1084-1088.
23. Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, Lukas J, Olsen K, Potter M, Reaves A, Rosenfeld P, Schachat AP, Strong HA, Wenkstern A: Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP report No. 2. Arch Ophthalmol 2003; 121: 1253-1268. (Pubitemid 37128403)
24. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58.
25. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.